Lead Physician: Francisco Maislos, M.D.
This Phase III active (Warfarin) controlled, randomized, double-blind, parallel-arm study is evaluating the efficacy and safety of Apixaban for use in preventing stroke and systemic embolism in subjects with non-valvular atrial fibrillation. Begun in August 2007, the trial will study 15,000 subjects for a minimum of four years.
Initiation Date: 2007-08-01
For more information: Contact Julia Powers, RN, MSN, CCRP, at 713.456.4011 or Kristin Chandler, RN, CCRP, at 713.456.4073.